BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lai JC, O’Leary JG, Trotter JF, Verna EC, Brown RS, Stravitz RT, Duman JD, Forman LM, Terrault NA. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl. 2012;18:532-538. [PMID: 22271671 DOI: 10.1002/lt.23396] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Stock PG, Terrault NA. Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle. Hepatology 2015;61:1747-54. [PMID: 25292153 DOI: 10.1002/hep.27553] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
2 Dhaliwal A, Dhindsa B, Ramai D, Sayles H, Chandan S, Rangray R. Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database. WJH 2022;14:985-92. [DOI: 10.4254/wjh.v14.i5.985] [Reference Citation Analysis]
3 Selzner N, Berenguer M. Should organs from hepatitis C-positive donors be used in hepatitis C-negative recipients for liver transplantation? Liver Transpl 2018;24:831-40. [DOI: 10.1002/lt.25072] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
4 Martin EF. Paradigm Shift in Utilization of Livers from Hepatitis C-Viremic Donors into Hepatitis C Virus-Negative Patients. Clin Liver Dis 2021;25:195-207. [PMID: 33978579 DOI: 10.1016/j.cld.2020.08.009] [Reference Citation Analysis]
5 Terrault NA, McCaughan GW, Curry MP, Gane E, Fagiuoli S, Fung JYY, Agarwal K, Lilly L, Strasser SI, Brown KA. International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017;101:945-955. [PMID: 28437387 DOI: 10.1097/tp.0000000000001708] [Cited by in Crossref: 57] [Cited by in F6Publishing: 12] [Article Influence: 14.3] [Reference Citation Analysis]
6 Kardashian AA, Price JC. Hepatitis C virus-HIV-coinfected patients and liver transplantation. Curr Opin Organ Transplant 2015;20:276-85. [PMID: 25944240 DOI: 10.1097/MOT.0000000000000199] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Bushyhead D, Goldberg D. Use of Hepatitis C-Positive Donor Livers in Liver Transplantation. Curr Hepatol Rep 2017;16:12-7. [PMID: 28243573 DOI: 10.1007/s11901-017-0327-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
8 Vodkin I, Kuo A. Extended Criteria Donors in Liver Transplantation. Clin Liver Dis. 2017;21:289-301. [PMID: 28364814 DOI: 10.1016/j.cld.2016.12.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
9 deLemos AS, Vagefi PA. Expanding the donor pool in liver transplantation: Extended criteria donors. Clin Liver Dis (Hoboken) 2013;2:156-9. [PMID: 30992852 DOI: 10.1002/cld.222] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
10 Campos-Varela I, Agudelo EZ, Sarkar M, Roberts JP, Terrault NA. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient. Transpl Infect Dis 2018;20. [PMID: 29125670 DOI: 10.1111/tid.12809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
11 Kahn JA. The use of organs from hepatitis C virus-viremic donors into uninfected recipients. Curr Opin Organ Transplant. 2020;25:620-625. [PMID: 33105203 DOI: 10.1097/mot.0000000000000826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Booth IA, Clark JE, LaMattina JC, Barth RN, Haririan A, Ravichandran BR. The Impact of Treatment Delay on Hepatitis C Liver Transplant Outcomes. J Pharm Pract 2021;:8971900211034261. [PMID: 34289722 DOI: 10.1177/08971900211034261] [Reference Citation Analysis]
13 Shetty A, Buch A, Saab S. Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients. Dig Dis Sci 2019;64:1110-8. [PMID: 30560331 DOI: 10.1007/s10620-018-5404-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Liapakis A, Formica RN, Levitsky J. Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. Curr Opin Organ Transplant 2018;23:257-63. [PMID: 29432255 DOI: 10.1097/MOT.0000000000000504] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
15 Brown K. Maximizing donors with viral hepatitis in the current era. Liver Transpl 2017;23:S44-9. [PMID: 28846183 DOI: 10.1002/lt.24863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kwong AJ, Wall A, Melcher M, Wang U, Ahmed A, Subramanian A, Kwo PY. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. Am J Transplant. 2019;19:1380-1387. [PMID: 30378723 DOI: 10.1111/ajt.15162] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 16.5] [Reference Citation Analysis]
17 Murag S, Dennis BB, Kim D, Ahmed A, Cholankeril G. Recent advances in liver transplantation with HCV seropositive donors. F1000Res 2019;8:F1000 Faculty Rev-2151. [PMID: 31942236 DOI: 10.12688/f1000research.20387.1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Patwardhan VR, Curry MP. Reappraisal of the hepatitis C virus-positive donor in solid organ transplantation. Curr Opin Organ Transplant. 2015;20:267-275. [PMID: 25944236 DOI: 10.1097/mot.0000000000000191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 Martini S, David E, Tandoi F, Dell Olio D, Salizzoni M, Saracco G, Romagnoli R. HCV viremic donors with hepatic bridging fibrosis: Are we ready to use their livers in the era of direct-acting antivirals? Am J Transplant 2017;17:2986-7. [DOI: 10.1111/ajt.14447] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
20 Stepanova M, Sayiner M, de Avila L, Younoszai Z, Racila A, Younossi ZM. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor. BMC Gastroenterol. 2016;16:137. [PMID: 27846801 DOI: 10.1186/s12876-016-0551-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
21 Campos-Varela I, Dodge JL, Stock PG, Terrault NA. Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus. Clin Transplant 2016;30:1140-5. [PMID: 27411037 DOI: 10.1111/ctr.12800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
22 Metin O, Şimşek C, Gürakar A. Update on liver transplantation-newer aspects. Turk J Med Sci 2020;50:1642-50. [PMID: 32222125 DOI: 10.3906/sag-2002-17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol. 2012;26:531-548. [PMID: 23199510 DOI: 10.1016/j.bpg.2012.09.010] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
24 Chhatwal J, Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DM, Chung RT. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017;65:777-788. [PMID: 27906468 DOI: 10.1002/hep.28926] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 12.4] [Reference Citation Analysis]
25 Dhaliwal A, Dhindsa B, Ramai D, Sayles H, Chandan S, Rangray R. Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database. World J Hepatol 2022; 14(5): 984-991 [DOI: 10.4254/wjh.v14.i5.984] [Reference Citation Analysis]
26 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
27 Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O'Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017;17:2790-2802. [PMID: 28556422 DOI: 10.1111/ajt.14381] [Cited by in Crossref: 202] [Cited by in F6Publishing: 175] [Article Influence: 40.4] [Reference Citation Analysis]
28 Berenguer M. Last gasps of the hepatitis C virus dragon: Direct acting antiviral failures and hepatitis C virus-positive donors. Liver Transpl 2016;22:47-51. [PMID: 27465590 DOI: 10.1002/lt.24520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Levitsky J, Doucette K; the AST Infectious Diseases Community of Practice. Viral Hepatitis in Solid Organ Transplantation: Viral Hepatitis. American Journal of Transplantation 2013;13:147-68. [DOI: 10.1111/ajt.12108] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 6.2] [Reference Citation Analysis]
30 Samur S, Kues B, Ayer T, Roberts MS, Kanwal F, Hur C, Donnell DMS, Chung RT, Chhatwal J. Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. Clin Gastroenterol Hepatol. 2018;16:115-122.e10. [PMID: 28634131 DOI: 10.1016/j.cgh.2017.06.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
31 Feng S, Lai JC. Expanded criteria donors. Clin Liver Dis 2014;18:633-49. [PMID: 25017080 DOI: 10.1016/j.cld.2014.05.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 7.1] [Reference Citation Analysis]
32 Coilly A, Samuel D. Pros and Cons: Usage of organs from donors infected with hepatitis C virus - Revision in the direct-acting antiviral era. J Hepatol. 2016;64:226-231. [PMID: 26375245 DOI: 10.1016/j.jhep.2015.09.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
33 O'Leary JG, Kaneku H, Jennings L, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transpl 2014;20:655-63. [PMID: 24678017 DOI: 10.1002/lt.23854] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
34 Dumortier J, Boillot O, Scoazec JY. Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: Past, present and future. World J Gastroenterol 2014; 20(32): 11069-11079 [PMID: 25170196 DOI: 10.3748/wjg.v20.i32.11069] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
35 Verna EC. Hepatitis viruses and liver transplantation: evolving trends in antiviral management. Clin Liver Dis. 2014;18:575-601. [PMID: 25017077 DOI: 10.1016/j.cld.2014.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
36 deLemos AS, Schmeltzer PA, Russo MW. Recurrent hepatitis C after liver transplant. World J Gastroenterol 2014; 20(31): 10668-10681 [PMID: 25152571 DOI: 10.3748/wjg.v20.i31.10668] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
37 Kahn J, Terrault NA. Intentional Transmission of Hepatitis C With Organ Transplantation: With Opportunity Comes Responsibility. Transplantation 2019;103:2215-6. [DOI: 10.1097/tp.0000000000002892] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]